Companies/Tenax Therapeutics, Inc.

Company profile

Tenax Therapeutics, Inc.

NASDAQ: TENX · Healthcare · Biotechnology

PublicHQ Chapel Hill, NC · OrangeCIK 0000034956Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

49D

FH 57DQ 34GM —SS 62

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, listing tenure · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$52.6M

Employees

as of 2026-08-13

Market cap

$45.6M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$52.6M-$52.6M2025

Operating income-$56.4M-$56.4M2025

Total assets$104.2M$104.2M2025

Liabilities$7.2M$7.2M2025

Equity$97.1M$97.1M2025

Revenue trend

FY2012 – FY2025 · USD

$475.3k

FY12

$1.7M

FY13

$158.9k

FY16

$49.3k

FY16

FY24

FY25

Revenue by segment

Filed disclosures · FY2013

By product

United States100%

By geography

Europe50%

United States50%

The read

What is Tenax Therapeutics, Inc.’s revenue?

Tenax Therapeutics, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Edesa Biotech, Inc.47D Arch Biopartners Inc.13D Instil Bio, Inc.36D Noveris Health Sciences Inc.——Grace Therapeutics, Inc.48D NanoViricides, Inc.35D

Neighbors

Orange →

Investors Title Company$40.9M70B James River Group Holdings, Ltd.$687.6M58C

Key facts

CEOChristopher T. Giordano

SectorHealthcare

IndustryBiotechnology

HeadquartersChapel Hill, NC

ExchangeNASDAQ: TENX

Employees15

IPO date1994-04-04

Latest filings

8-K2026-07-02 8-K2026-06-30 8-K2026-06-29 8-K2026-06-04 10-Q2026-05-12 8-K2026-05-12 8-K2026-04-22 DEF 14A2026-04-22

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.